RxDoctor Payments DataLook up a doctor →

Brian Drachman, MD

Cardiovascular Disease · Philadelphia, PANPI 1801827597

Payments from drug & device makers

$3,799,477in general payments, 2019–2025

Across 403 payments — averaging $9427.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$3.1M
  • Pfizer$451K
  • AstraZeneca$209K
  • Ionis Pharmaceuticals, Inc.$29K
  • Eidos Therapeutics, Inc.$29K
  • Akcea Therapeutics, Inc.$500
  • plus $59 from 3 others
$34,370in research payments, 2019–2025

Across 23 payments — averaging $1494.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$34K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,799,477 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$164,853
Medicare patients
650
Services billed
2,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →